Holen Sie sich die Stockscreener-App
0.00
100.00%
-4.97
Schlusskurs vom Vortag:
$4.97
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$48.77M
Einnahmen:
$21.73M
Nettoeinkommen (Verlust:
$-91.17M
KGV:
0.00
EPS:
-0.74
Netto-Cashflow:
$-286.43M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$15.40
Bluebird Bio Inc Stock (BLUE) Company Profile
Firmenname
Bluebird Bio Inc
Sektor
Branche
Telefon
339-499-9300
Adresse
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Vergleichen Sie BLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
0.00 | 48.77M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-11-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-11-15 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-12-11 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2023-12-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-19 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-11-08 | Bestätigt | Barclays | Equal Weight |
| 2021-11-08 | Bestätigt | Canaccord Genuity | Hold |
| 2021-11-08 | Herabstufung | Goldman | Neutral → Sell |
| 2021-11-08 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | Bestätigt | Wedbush | Neutral |
| 2021-11-08 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-08-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | Fortgesetzt | William Blair | Mkt Perform |
| 2021-08-09 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | Herabstufung | Berenberg | Buy → Hold |
| 2021-03-10 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-02-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-02-16 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-16 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2020-11-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | Eingeleitet | Mizuho | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-27 | Hochstufung | Stifel | Hold → Buy |
| 2020-02-19 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-02-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Hold |
| 2019-08-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | Hochstufung | Maxim Group | Hold → Buy |
Alle ansehen
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
Will earnings trigger a reversal in bluebird bio Inc.Quarterly Profit Report & Weekly Watchlist for Consistent Profits - newser.com
Will bluebird bio Inc. see short term momentumWeekly Profit Analysis & Breakout Confirmation Alerts - newser.com
Should I hold or sell bluebird bio Inc. stock in 20252025 Volatility Report & Target Return Focused Stock Picks - nchmf.gov.vn
What Wall Street predicts for bluebird bio Inc. stock priceAnalyst Upgrade & AI Based Buy and Sell Signals - newser.com
Is bluebird bio Inc. stock a smart buy before Fed meetingJuly 2025 Market Mood & Detailed Earnings Play Strategies - nchmf.gov.vn
What technical signals suggest for bluebird bio Inc. stockJuly 2025 Retail & Daily Chart Pattern Signals - newser.com
Lobbying Update: $60,000 of GENETIX BIOTHERAPEUTICS INC. (FORMERLY BLUEBIRD BIO INC.) lobbying was just disclosed - Quiver Quantitative
Is bluebird bio Inc. stock supported by strong fundamentalsWeekly Risk Report & Entry Point Confirmation Signals - newser.com
Car T Cell Therapy For Multiple Myeloma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary - Barchart.com
United States Adrenoleukodystrophy Treatment Market - openPR.com
Pattern recognition hints at bluebird bio Inc. upsideMarket Sentiment Summary & Daily Price Action Insights - newser.com
The commercial real estate media source. - NEREJ
Regeneron backs bluebird with $100 mn, jointly work on cancer therapies - Entrepreneur India
Has bluebird bio Inc. formed a bullish divergenceJuly 2025 Short Interest & Fast Entry and Exit Trade Plans - newser.com
Analyzing recovery setups for bluebird bio Inc. investorsWeekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com
News impact scoring models applied to bluebird bio Inc.Market Sentiment Summary & Technical Entry and Exit Tips - newser.com
Will bluebird bio Inc. benefit from macro trendsWeekly Trade Report & Technical Confirmation Trade Alerts - newser.com
Will bluebird bio Inc. bounce back from current supportDay Trade & Low Risk Investment Opportunities - newser.com
Is bluebird bio Inc a good long term investmentRisk Management Strategies & Free Explosive Wealth Accumulation - earlytimes.in
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio LawsuitBLUE - MarketScreener
Chart based analysis of bluebird bio Inc. trends2025 Sector Review & Low Risk High Reward Ideas - newser.com
Is bluebird bio Inc. showing signs of accumulationForecast Cut & Short-Term Trading Alerts - newser.com
Former bluebird CEO picked to lead Inventiva - biocentury.com
What’s the recovery path for long term holders of bluebird bio Inc.Weekly Market Report & Low Volatility Stock Recommendations - newser.com
Gene Therapy for Rare Disease Market to Reach US$ 24.54 Bn by 2033, - openPR.com
Finanzdaten der Bluebird Bio Inc-Aktie (BLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):